Benepali: The leading etanercept in Europe1,a

Benepali (etanercept) indications

Benepali™ (etanercept) is indicated for the treatment of immune-mediated inflammatory diseases (rheumatological and dermatological diseases).

a Benepali™ is the etanercept market leader in the combined pharmaceutical markets in Europe where Benepali™ is launched and where we have data from IQVIA/MIDAS. Calculation based on single units (SU). Markets are: Austria, Belgium, Czech Rep, Denmark, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK.

Dermatological
diseases

Rheumatological
diseases

How to use Benepali (etanercept) pen and syringe

Key safety information to help with Benepali™ (etanercept) use in clinical practice.

Benepali pre-filled pen

  • Audible Double Click3 – Confirms correct dosing, ensures intended benefit
  • Compact and Lightweight4 – Discrete and portable for patients
  • Latex Free2 – Reassurance for patients with latex allergy or their family
  • Medication Window3 – Confirms full dose delivery, maximising patient benefit
  • Button-free5 – Simple to use

Benepali pre-filled syringe

 

  • Stainless Steel6 – 27 gauge needle
  • Needle cover3
  • Plunger3
  • Latex Free2 – Reassurance for patients with latex allergy or their family
  • Ergonomic Finger Grip5